Avalon Pharma
أفالون فارماTechnical Analysis & Signals
Avalon Pharma stock shows relative stability in the Saudi market with a sideways trend.
Technical Analysis
The current price of Avalon Pharma stock is at 60.55 SAR, indicating a slight decline of 0.25%. The Relative Strength Index (RSI) is at 53.6, suggesting that the stock may be in a neutral zone.
Support & Resistance Levels
The main support level is at 59.56 SAR, while the resistance level is at 61.96 SAR. The stock is expected to face challenges as it approaches the resistance level.
Volume Analysis
No volume data is currently available, which may indicate a decrease in trading activity. This could potentially affect the price movement in the future.
Fundamental Factors
The price-to-earnings (P/E) ratio is at 20.3, indicating a moderate valuation for the stock. The dividend yield is at 2.56%, which may attract some investors seeking steady income.
Risk Factors
Avalon Pharma faces risks related to the current sideways trend, which may impact potential returns. Additionally, fluctuations in the Saudi market and the TASI index may affect the stock's performance.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Investors are advised to monitor support and resistance levels before making any investment decisions.
Financial Fundamentals
Price Data
Price Chart - Avalon Pharma
4016Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 2.12B
- P/E Ratio
- 20.30
- P/B Ratio
- 5.10
- EPS (Earnings/Share)
- 2.98
Profitability
- Revenue
- 512.08M
- Net Income
- 108.50M
- Return on Equity (ROE)
- 0.00%
- Shares Outstanding
- 35.00M
Balance Sheet
- Total Assets
- 599.53M
- Total Debt
- N/A
- Debt/Equity
- 0.20
- Free Float %
- +46.9%
Dividends & Margins
- Dividend Yield
- +2.56%
- Dividend/Share
- 1.55
- Book Value
- 11.87
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
3 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 460.48M +16.9% | 97.01M +21.5% | 599.53M +13.8% | 63.84M +0.9% | 2.77 +21.5% |
| 2024 | 394.00M +16.4% | 79.85M +21.3% | 526.78M +16.4% | 63.26M +2.0% | 2.28 +21.3% |
| 2023 | 338.44M | 65.83M | 452.74M | 62.00M | 1.88 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
No news currently available for Avalon Pharma
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-08-12
Risk Assessment
Risk Factors
Average True Range 1.7% of stock price
Trading volume below average
P/E ratio 20.3
Debt-to-equity ratio 0.20
ADX indicator at 18 — no clear direction
Moderate risk factors with some sector pressures
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Avalon Pharma stock price today?
Avalon Pharma (4016) stock price today is 60.55 SAR, declining by -0.25% compared to the previous session close. The 52-week price range is between 53.16 SAR and 78.02 SAR.
2 What is Avalon Pharma stock valuation?
The automated analysis signal for Avalon Pharma is "Hold" with 65% confidence. The P/E ratio is 20.3. The P/B ratio is 5.10.
3 Is Avalon Pharma Shariah-compliant?
Yes, Avalon Pharma (4016) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Avalon Pharma dividend distributions?
Avalon Pharma has a dividend yield of 2.56%, with an estimated annual dividend of 1.55 SAR per share.
5 What is Avalon Pharma weekly performance?
Avalon Pharma performance over different time periods: weekly change +2.98%, monthly -2.81%, and year-to-date -4.95%. The stock is currently trading with a volume of 22,579 shares.
6 What is the target level for Avalon Pharma?
According to automated analysis for Avalon Pharma: Short-term target (1-2 weeks): 62.08 SAR. Support level: 59.56 SAR. Resistance level: 61.96 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.